Get the Stockscreener App
14.03
1.02%
0.26
Novocure Ltd stock is traded at $14.03, with a volume of 39,582.
It is up +1.02% in the last 24 hours and up +14.86% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$13.77
Open:
$13.68
24h Volume:
39,582
Relative Volume:
0.02
Market Cap:
$1.58B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-10.02
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
+5.22%
1M Performance:
+14.86%
6M Performance:
-21.46%
1Y Performance:
-53.10%
1-Day Range:
$13.68
$14.09
1-Week Range:
$12.88
$13.94
52-Week Range:
$10.70
$29.80
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.09 | 1.54B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
128.91 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.86 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
357.29 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.12 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.02 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Voya Investment Management LLC Sells 64,539,786 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Why NovoCure Limited stock could be next big winnerChart Pattern Recognition & View Live Stock Forecasts Instantly - bollywoodhelpline.com
NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows - Yahoo Finance UK
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound - simplywall.st
Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump? - Yahoo Finance
Novocure (NVCR) Q2 2025 Earnings Call Transcript - AOL.com
NovoCure (NVCR) Q3 2024 Earnings Call Transcript - The Globe and Mail
First Week of February 2026 Options Trading For NovoCure (NVCR) - Nasdaq
How to hear Novocure’s CEO speak at the J.P. Morgan healthcare event - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
MACD Signal: How analysts rate NovoCure Limited stock todayTrend Reversal & Capital Efficient Trade Techniques - Улправда
How analysts rate NovoCure Limited stock todayCEO Change & Smart Money Movement Tracker - Улправда
CapEx per share of NovoCure Ltd. – MUN:038 - TradingView — Track All Markets
Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail
NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st
Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Price Up 7%Time to Buy? - MarketBeat
What is the fair value estimate for NovoCure Limited (038) stock in 2025Weekly Trade Report & Verified Stock Trade Ideas - Newser
Edgestream Partners L.P. Increases Holdings in NovoCure Limited $NVCR - Defense World
Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025? - Yahoo Finance
NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc. - MarketBeat
NovoCure stock rating reiterated at Buy by H.C. Wainwright amid CEO change - Investing.com Nigeria
NovoCure (NASDAQ:NVCR) Shares Gap DownShould You Sell? - MarketBeat
Can NovoCure's Tumor Treating Fields Redefine Cancer Care By 2026? - RTTNews
Novocure names Frank Leonard as new CEO, replacing Ashley Cordova By Investing.com - Investing.com Australia
How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm - simplywall.st
Novocure CEO Ashley Cordova resigns, Frank Leonard succeeds - TipRanks
Novocure (NVCR) Appoints New CEO Amid Leadership Change - GuruFocus
Novocure names Frank Leonard as new CEO, replacing Ashley Cordova - Investing.com India
Novocure Ltd Announces CEO Transition - TradingView
Novocure (NASDAQ: NVCR) elevates President Frank Leonard to CEO as Ashley Cordova resigns - Stock Titan
Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Novocure (NASDAQ: NVCR) to Present at 37th Piper Sandler Healthcare Conference on Dec. 2 - Stock Titan
NovoCure Limited (NVCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will NovoCure Limited stock attract more institutional investorsInsider Buying & Breakout Confirmation Trade Signals - newser.com
Novocure at Jefferies London: Expanding Horizons in Cancer Treatment By Investing.com - Investing.com South Africa
Tangible book value per share of NovoCure Ltd. – DUS:038 - TradingView
Published on: 2025-11-19 05:31:32 - newser.com
Will NovoCure Limited stock benefit from green energy trendsPrice Action & AI Forecasted Entry/Exit Points - newser.com
Novocure at Jefferies London: Expanding Horizons in Cancer Treatment - Investing.com India
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.45%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):